Hui Shao, M.D., Ph.D.
Assistant Professor
Department:
Pharmaceutical Outcomes & Policy
Business Phone:
(352) 294-8323
Business Email:
hui.shao@ufl.edu
About Hui Shao
Hui Shao is currently an assistant professor at the University of Florida’s College of Pharmacy, within the Department of Pharmaceutical Outcomes and Policy. One of his core research areas is predictive modeling, using advanced machine learning, microsimulation, and econometrics method to build valid predictive models to resolve real-world issues. Hui is one of the original developer of the Building, Relating, Assessing, and Validating Outcomes (BRAVO) diabetes model, which is the first person-level microsimulation model predicting the progression of diabetes based on individuals’ characteristics and treatment regimen, in the U.S. Hui is currently working with the Centers for Disease Control and Prevention on multiple projects, oversees the development process of several national diabetes/prediabetes predictive models.
Accomplishments
Kaafee Billah Early Career Researcher Award
2020
·
Centers for Disease Control and Prevention
Early Career Innovator Award
2019
·
Centers for Disease Control and Prevention
Adjunct Professor
2017-Current
·
Tulane University, School of Public health and Tropical Medicine, Department of Health Policy and Management
Honored Award
2017
·
Patient Access Network (PAN)
Best Student Podium
2016
·
ISPOR, Washington DC
Best Student Poster
2014
·
Academy Health Annual Research Meeting, San Diego
Dean of the School of Public Health and Tropical Medicine Award
2013
·
Tulane University
Teaching Profile
Courses Taught
2020-2023
PHA5267 Prin Pharm-Economics
2020-2023
PHA6935 Selected Topics in Pharmacy
2020-2023
PHA6910 Supervised Research
2020-2023
PHA7979 Advanced Research
2020-2021
PHA7980 Research for Doctoral Dissertation
2019
PHA5878C Pt Care 3: Cv and Pulm
2021-2023
PHA6937 Topics in Pharmaceutical Administration
2021-2023
PHA6940 Supervised Teaching
2021-2022
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2021-2023
PHA6936 Advanced Topics in Pharmaceutical Sciences
2021-2023
PHA6971 Research for Master’s Thesis
2021-2023
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
Research Profile
Research interests: Diabetes, Disease Progression Modeling/Simulation, Machine Learning and Artificial Intelligence, Health Economics and Outcomes Research, Health Technology Assessment/ Policy Evaluation, Advanced Econometrics
Open Researcher and Contributor ID (ORCID)
0000-0002-4088-546X
Publications
2022
A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015
Value in Health.
[DOI] 10.1016/j.jval.2022.02.011.
2022
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and
HbA1c
in
US
adults with diabetes: 2005‐2018
Diabetes, Obesity and Metabolism.
[DOI] 10.1111/dom.14894.
2022
Economic Evaluation of the $35 Insulin Copay Cap Policy in Medicare and Its Implication for Future Interventions
Diabetes Care.
[DOI] 10.2337/dc22-1230.
2022
Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study
Journal of Diabetes and its Complications.
36(3)
[DOI] 10.1016/j.jdiacomp.2022.108132.
2022
Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge
Medical Decision Making.
42(5):599-611
[DOI] 10.1177/0272989×211065479.
2022
Newer
glucose‐lowering
drugs and risk of dementia: A
meta‐analysis
of cardiovascular outcome trials
Journal of the American Geriatrics Society.
[DOI] 10.1111/jgs.17895.
2022
Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes
JAMA Network Open.
5(4)
[DOI] 10.1001/jamanetworkopen.2022.7705.
2022
Predicting incident heart failure among patients with type 2 diabetes mellitus: The
DM‐CURE
risk score
Diabetes, Obesity and Metabolism.
24(11):2203-2211
[DOI] 10.1111/dom.14806.
2022
Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare
Diabetes Care.
45(8):1814-1821
[DOI] 10.2337/dc21-2601.
2022
Selecting a target population for type 2 diabetes lifestyle prevention programs: A cost‐effectiveness perspective
Diabetic Medicine.
39(7)
[DOI] 10.1111/dme.14847.
2022
Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes
Diabetes Care.
45(2):e32-e33
[DOI] 10.2337/dc21-1800.
2022
Syndromic Surveillance Systems for Mass Gatherings: A Scoping Review
International Journal of Environmental Research and Public Health.
19(8)
[DOI] 10.3390/ijerph19084673.
[PMID] 35457541.
2021
A varied approach to left ventricular assist device follow-up improves cost-effectiveness.
Current medical research and opinion.
[DOI] 10.1080/03007995.2021.1948395.
[PMID] 34181489.
2021
Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study
Journal of Diabetes and its Complications.
[DOI] 10.1016/j.jdiacomp.2021.107972.
2021
Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without alzheimer’s disease and related dementias (ADRD)
Current Medical Research and Opinion.
1-1
[DOI] 10.1080/03007995.2021.1953972.
[PMID] 34252317.
2021
Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes
Value in Health.
24(2):227-235
[DOI] 10.1016/j.jval.2020.09.010.
2021
Patient Health Utility Equations for a Type 2 Diabetes Model
Diabetes Care.
44(2):381-389
[DOI] 10.2337/dc20-1207.
[PMID] 33277301.
2021
The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010–2018
Current Medical Research and Opinion.
37(11):1875-1880
[DOI] 10.1080/03007995.2021.1971181.
2021
The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
Lancet (London, England).
396(10267):2019-2082
[DOI] 10.1016/S0140-6736(20)32374-6.
[PMID] 33189186.
2021
Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018
Diabetes Care.
44(10):e180-e182
[DOI] 10.2337/dc20-2529.
2021
Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018
Diabetes Care.
44(4):925-934
[DOI] 10.2337/dc20-2871.
2020
A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes
Current Diabetes Reports.
20(4)
[DOI] 10.1007/s11892-020-1292-5.
2020
Association between frailty and life satisfaction among older people in Shandong, China: the differences in age and general self‐efficacy
Psychogeriatrics.
20(2):172-179
[DOI] 10.1111/psyg.12482.
2020
Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis
BMC Medicine.
18(1)
[DOI] 10.1186/s12916-020-01837-x.
[PMID] 33267884.
2020
Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. Diabetes Care 2019;42:2298–2306
Diabetes Care.
43(2):e25-e25
[DOI] 10.2337/dc19-1891.
[PMID] 31959647.
2020
Does the Encounter Type Matter When Defining Diabetes Complications in Electronic Health Records?
Medical Care.
58:S53-S59
[DOI] 10.1097/mlr.0000000000001297.
2020
Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge
Value in Health.
23(9):1163-1170
[DOI] 10.1016/j.jval.2020.04.1832.
2020
Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017
Diabetes Care.
43(10):2396-2402
[DOI] 10.2337/dc19-2273.
[PMID] 32737138.
2020
Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study
Diabetes Care.
43(11):2847-2852
[DOI] 10.2337/dc20-0465.
[PMID] 32887705.
2020
Implementing Lifestyle Change Interventions to Prevent Type 2 Diabetes in US Medicaid Programs: Cost Effectiveness, and Cost, Health, and Health Equity Impact
Applied Health Economics and Health Policy.
18(5):713-726
[DOI] 10.1007/s40258-020-00565-w.
[PMID] 32607728.
2020
Selecting the optimal risk threshold of diabetes risk scores to identify high-risk individuals for diabetes prevention: a cost-effectiveness analysis
Acta Diabetologica.
57(4):447-454
[DOI] 10.1007/s00592-019-01451-1.
[PMID] 31745647.
2020
Statin Use for Atherosclerotic Cardiovascular Disease Prevention Among Sexual Minority Adults
Journal of the American Heart Association.
9(24)
[DOI] 10.1161/jaha.120.018233.
2020
Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study
Journal of Clinical Medicine.
9(8)
[DOI] 10.3390/jcm9082332.
[PMID] 32707877.
2020
Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors
Diabetes Care.
43(7):1530-1536
[DOI] 10.2337/dc20-0227.
[PMID] 32345650.
2019
Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis
Diabetes Care.
42(11):2136-2142
[DOI] 10.2337/dc19-0381.
2019
Policy options for addressing the high cost of specialty pharmaceuticals
Global Health Journal.
3(4):79-83
[DOI] 10.1016/j.glohj.2019.11.005.
Grants
Sep 2022
ACTIVE
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV
via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
ACTIVE
Assessing Barriers and Facilitators for Participating Structured Lifestyle Intervention and Its Real-world Effectiveness and Cost-effectiveness among US Veterans
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2022
ACTIVE
Building Equity Improvement into Quality Improvement in the use of New Glucose-lowering Drugs (GLDs) through Individualized Drug Value Assessment in People with Diabetes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDDK
Sep 2020
ACTIVE
Using Real-world Data to Assess the Burden of Diabetes in Children and Adolescents in Florida
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2020
– Sep 2022
Louisiana Experiment to Address Diabetes: Zero-Dollar Copayment (LEAD-ZDC) for Improving Disease Management
Role: Principal Investigator
Funding: TULANE UNIV
via CTRS FOR DISEASE CONTROL AND PREVENTION
Jul 2020
– Jul 2021
Simulating Long-Term Outcomes for iGlarlixi using BRAVO Diabetes Model
Role: Principal Investigator
Funding: TULANE UNIV
via SANOFI
Jun 2020
– Jun 2022
CDC IPA – Assignment Agreement 20IPA2008335DPG
Role: Principal Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Education
Ph.D.
2017
·
Tulane University
MHA
2012
·
Shandong University
M.D.
2010
·
Shandong University
Contact Details
Phones:
- Business:
- (352) 294-8323
Emails:
- Business:
- hui.shao@ufl.edu
Addresses:
- Business Mailing:
-
PO Box 100496
GAINESVILLE FL 32610 - Business Street:
-
1225 Center Dr, HPNP 3339
Gainesville FL 32601
Recent news
Dr. Hui Shao elected Director of Academics for the China Health Policy and Management Society
As Director of Academics, Shao will organize CHPAMS’ annual conference and develop two webinar series focused on introducing advanced methods in health economics and health services research and issues-driven research…
Dr. Hui Shao earns Early Career Award from CDC
The Centers for Disease Control and Prevention, or CDC, Health Economics Research Group bestowed Hui Shao, M.D., Ph.D., an assistant professor of pharmaceutical outcomes and policy, with the Kaafee Billah…